**ALU 301-2 References**

**References**

1. Binder, V, Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998 Nov-Dec:16(6):351-5.
2. Achkar JP, Lashner BA, Genetics of Inflammatory Bowel Disease. Medscape 2002 [www.medscape.com](http://www.medscape.com)
3. Podolsky, DK, Inflammatory Bowel Disease. N Engl J Med, 8 Aug 2002, Vol. 347, No.6. 417-429.
4. Karban A, Okazaki T, Panhuysen CI, et al. Functional Annotation of a Novel NFKB1 Promoter Polymorphism that Increases Risk for Ulcerative Colitis. Human Mol Genetics. 1 Jan 2004.
5. Brant SR, Panhuysen CIM, Nicolae D, et al. MDR1 Ala893 Polymorphism is Associate with Inflammatory Bowel Disease. Am J Hu Gen. Dec 2003.
6. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004 May; 126(6):1504-17.
7. Crohn’s & Colitis Foundation of America. Facts about the epidemiology of Inflammatory Bowel Diseases (IBD). [www.ccfa.org](http://www.ccfa.org)
8. Karlinger K, Gyorke T, Mako E, et al. The epidemiology and the pathogenesis of inflammatory bowel disease. European J of Rad 35(2000) 154-167.
9. Knigge, KL. Inflammatory Bowel Disease. Clin Cornerstone 2002 4(4) 49-60.
10. Fauci, AS, Braunwald, E, Isselbacher KJ, et al. Harrison’s Principles of Internal Medicine. 14th ed. 1633-1645.
11. Rowe, WA. Inflammatory Bowel Disease. [www.emedicine.com](http://www.emedicine.com). Updated 9 June 2004.
12. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004 Apr 5; 116 Suppl 7A:44S-49S.
13. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535.
14. Krok, KL, Lichtenstein, GR. Colorectal Cancer in Inflammatory Bowel Disease. Curr Opin Gastroenterol 2004 20 (1): 43-48.
15. Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel dis. 2003;9: 205-209.
16. Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and /or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2004;(2): CD000279.
17. Sands, BE, Anderson FH, Bernstein CN. Infliximab maintenance therapy for fistulizing Crohn’s Disease. N Engl J Med 2004. 350; 876-885.
18. Lim, WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004;4(2): 66-85.
19. Brackenridge RDC, Elder WJ. Medical Selection of Life Risks. 4th ed. 641-644.
20. Delco F, Sonnenberg A. Birth-cohort phenomenon in the time trends of mortality from ulcerative colitis. Am J Epidemiol 1999;150(4):359-366.
21. Delco F, Sonnenberg A. Commonalities in the time trends of Crohn’s disease and ulcerative colitis. Am J Gastroenterol. 1999;94(8):2171-2176.
22. Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population - based cohort study. Gastroent 2003;125:1583-1590.
23. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota from 1970 Through 2010. Clin Gastroenterol Hepatol. 2017; 15 (6): 857
24. Ekbom A, Helmick C, Zack M, Adami HO; The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991; 100 (2): 350
25. Kuzela L, Vavrecka A, Prikazska M, Drugda B, Hronec J, Senkova A, Drugdova M, Oltman M, Novotna T, Brezina M, Kratky A, Kristufek P. Hepatogastroenterology. 1999; 46 (27): 1714
26. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982-2010. Clin Gastroenterol Hepatol. 2013 Jan; 11(1): 43-8